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DNA immunization permits evaluation of possible antagonistic or synergistic effects between the encoded components.
The protein expression capacity in vitro was related to the immunogenicity in vivo of plasmids encoding the HIV-1 regulatory
genes tat rev, and nef. Neither Tat nor Rev expression was influenced by co-expression in vitro of all three proteins, while
Nef expression was slightly inhibited. With the combination of genes, the T-cellular responses of mice against Rev and Nef
were inhibited compared with those when single gene immunization was used. No interference was detected for the Tat
T-cell response. Thus, co-immunization with certain genes may result in inhibition of specific immune responses. © 2001
Academic Press
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DNA immunization has been shown to generate hu-
moral and cellular immune responses to a number of
pathogens in various animal models and primates, in-
cluding humans (Calarota et al., 1998; Donnelly et al.,
1997; MacGregor et al., 1998; Robinson et al., 1993; Ugen
et al., 1998; Wang et al., 1998). Only a few studies have
been published on the use of combined genes or multi-
valent DNA vaccines (Braun et al., 1998; Cardoso et al.,
1998; Grifantini et al., 1998; Hinkula et al., 1997a; Mc-
Clements et al., 1996). Co-immunization of mice with
genes from the measles virus (Cardoso et al., 1998)
resulted in an antibody subclass switch from an IgG2a-
type response elicited by nucleoprotein alone to an IgG1
response when combined with hemagglutinin. This indi-
cates that co-expression of different proteins can inter-
fere with the type of responses induced.
Recent data indicate that immune reactivity to the early
proteins Tat, Rev, and Nef of human immunodeficiency
virus type 1 (HIV-1) or recombinants between simian and
human immunodeficiency virus (SHIV) may contribute to
protection from primary infection or progression of dis-
ease (Cafaro et al., 1999; Calarota et al., 1998; Osterhaus
et al., 1999). High-level transcription from the integrated
provirus is regulated by the viral protein Tat and several
cellular cofactors (Bieniasz et al., 1998; Parada and Roe-1 To whom reprint requests should be addressed. Fax: 146 (8) 33 72
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46der, 1999; Wei et al., 1998). The viral protein Rev exports
the intron containing viral mRNA transcripts from the
nucleus to the cytoplasm (Feinberg and Greene, 1992)
with the aid of several cellular cofactors (Fritz et al., 1995;
Murphy and Wente, 1996). The viral protein Nef down-
regulates both CD4 receptors and molecules of the ma-
jor histocompatibility complex (MHC) class I from the
surface of infected cells (Aiken et al., 1996; Cohen et al.,
1999; Harris, 1996; Schwartz et al., 1996). Nef is also
suspected to disrupt normal T-cell signaling (Khan et al.,
1998; Piguet and Trono, 1999).
By inducing immune responses to the regulatory pro-
teins of HIV-1, it should be feasible to prevent the burst of
newly synthesized virions from infected cells and thereby
limit primary and chronic infection. We have previously
studied the immunogenicity of these genes in a combi-
nation with structural genes in several mouse strains
(Hinkula et al., 1997a,b). Not until now, however, has it
been feasible directly to analyze the interactions be-
tween the plasmids on the level of gene expression and
to study the influence on immunogenicity in the combi-
nation of plasmids. Quantification of the tat, rev, or nef
gene expression in the combination of plasmids was not
done in the previous study (Hinkula et al., 1997b).
In the present study, we have studied the genes in
identical backbone vectors, encoding the neomycin/
kanamycin resistance gene, the polyA signal from hu-
man papilloma virus type 16 (HPV 16) in a pUC-8-derived
vector backbone. We compared gene interaction at the
level of protein expression with the immunogenicity in
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47INTERACTIONS OF HIV DNA IMMUNOGENS IN VIVOvivo to identify possible interference or synergy between
the plasmids. Interference was detected in nef expres-
sion capacity when tat- and rev-encoding plasmids were
present. The immunogenicity of the rev and nef genes
as influenced by the presence of the other two proteins
ith decreased T cellular responses. We therefore sug-
est that administration of the early genes of HIV-1 as
ingle immunogens should be considered for optimal
rotein expression and strong immunogenicity.
RESULTS
Cloning, plasmid characterization and
in vitro expression
The coding sequences for full-length tat, rev, and nef
of HIV-1 LAI were cloned into the vector pKCMV by PCR
methods and were designated pKCMVtat, pKCMVrev,
nd pKCMVnef (Fig. 1). The plasmids were characterized
y restriction enzyme analysis and sequence analysis of
he promoter, insert, and polyA sequence. Single nucle-
tide changes were noted, though only one amino acid
aa) change had occurred; the Nef protein had a substi-
ution at aa 133 from Ile to Thr. As Thr at aa 133 occurs
FIG. 1. Schematic drawing of the three DNA vectors used. All three pl
, the nucleotide location of murine (GACGTC) immunostimulatory Cpn several viral isolates, the plasmid was accepted. West-
rn blotting (Fig. 2) and indirect immunofluorescenceFig. 3), using HeLa cells transfected with the different
lasmid constructs and the empty vector as control,
onfirmed the in vitro expression of single plasmid for-
ulations. Twenty-four hours after transfection, the ma-
ority of Tat, Rev, and Nef proteins could be detected in
he cytoplasm. The molecular weight of Tat was found to
e ;16 kDa, of Rev ;19 kDa, and of Nef ;27 kDa. The
have approximately the same length. Km, Kanamycin resistance gene;
s; *, the location of the human (AACGTCGA) CpG motif.
FIG. 2. (A) Tat expression from pKCMVtat. Expression was detected
with Tat-specific mouse monoclonal antibodies in 1:500 dilution (1) or
1:1500 dilution (2) and with Tat specific rabbit polyclonal antibodies in
1:500 dilution (3) or 1:1500 dilution (4). (B) Rev expression from
pKCMVrev detected with Rev-specific mouse monoclonal antibodies in
1:500 dilution (1) or 1:1500 dilution (2) and with Rev specific rabbit
polyclonal antibodies in 1:1500 dilution (3) or 1:500 dilution (4). (C) Nef
expression from pKCMVnef detected with Nef-specific mouse mono-
clonal antibodies in 1:500 dilution (1) or 1:1500 dilution (2) and with
Nef-specific rabbit polyclonal antibodies in 1:1500 dilution (3) or 1:500
dilution (4). Detection was performed on HeLa cells transfected with
the different constructs followed by detection using an ECL kit.
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48 KJERRSTRO¨M ET AL.additional band seen close to the in the Tat Western blot
is due to insufficient reduction of the internal disulfide
bonds present in the Tat protein.
The presence of immunostimulatory motifs was inves-
tigated in pKCMVtat, pKCMVrev, pKCMVnef, and pKCMV.
ll plasmids contain five murine immunostimulatory mo-
ifs (GACGTC) and one human stimulatory motif
AACGTCGA) (Fig. 1). No immunostimulatory motifs were
ound in the tat, rev, or nef open reading frames.
FIG. 3. Transient expression of Tat (A), Rev (B), Nef (C), and the empty
vector pKCMV (D). Indirect immunofluorescence was performed on
HeLa cells transfected with the pKCMVtat, pKCMVrev, pKCMVnef, or
KCMV constructs using polyclonal rabbit sera against the respective
rotein. The majority of protein expression was detected in the cytol-
lasm 24 h after transfection.
FIG. 4. Tat-dependent CAT expression in vitro. CAT expression was d
and CAT-expressing plasmid. HCMVtat was included as a positive con
0.5 mg of DNA. The pBluescript alone was transfected with 2 mg. TheNA. In all cases, the total DNA amount was adjusted to 2 mg of DNA, using
data of several experiments and standard errors. The single (o) gene expresTat expression
Quantitative Tat-dependent CAT expression in vitro
was examined in tat co-transfected HeLa cells, followed
by detection of CAT protein by a CAT-specific ELISA (Fig.
4). No interference of Tat transcriptional activity was
apparent when all three genes (tat, rev, and nef) were
combined in the co-transfection assay compared to
when the tat gene was expressed alone. HCMVtat (Ca-
larota et al., 1998) was included each time as a positive
control. HCMVtat is identical to pKCMVtat except that the
former encodes the ampicillin-resistance gene and the
latter the kanamycin-resistance gene. Untransfected
cells, pNLCATw, pBluescript, HCMVtat alone, pKCMVtat
alone, and the mixture of the three pKCMVtat, pKCMVrev,
and pKCMVnef coding vectors without pNLCATw were
included as negative controls and did not result in CAT
production.
Rev expression
Quantitative Rev-dependent p24 production in vitro
was investigated in HeLa cells transfected with the rev
gene followed by p24 detection (Fig. 5). The co-expres-
sion of Tat and Nef with Rev did not show any interfer-
ence with the biological activity of the expressed Rev
protein. The plasmid pBrev (the rev gene under the con-
trol of HIV-1 LTR, see Materials and Methods) was in-
cluded as a positive control. Untransfected cells, pBlue-
script, HCMVtat 1 p24, pBrev 1 p24, pKCMVrev 1 p24,
pKCMVtat, rev, and nef alone were included as negative
controls. Positive p24 values in the control transfections
in HeLa cells co-transfected with the respective tat-encoding plasmid
nsfection with the pNLCATw plasmid was consistently performed with
oding plasmids in the negative controls were transfected with 1 mg ofetected
trol. Tra
tat-encthe pBluescript non-coding plasmid. The figure shows representative
sion is compared with the combined (n) column.
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49INTERACTIONS OF HIV DNA IMMUNOGENS IN VIVOare due to the natural Rev-independent p24 production
from the p24-encoding plasmid.
Nef expression
Nef in vitro expression capacity was evaluated in HeLa
ells transfected with the nef gene, and a sandwich ELISA
FIG. 5. Rev-dependent p24 expression in vitro. p24 is produced from
lasmid, and a p24-expressing plasmid. The plasmid pBrev is included
ere consistently performed with 0.5 mg of DNA. As negative controls
the rev-encoding plasmid DNA alone. In all transfections, the total DNA
figure shows representative data of several experiments and standard
olumn.
FIG. 6. Nef expression in vitro. Nef is produced from HeLa cells tran
ositive control. HeLa cells were transfected with either 2 mg of the etransfections, the total DNA amount was adjusted to 2 mg using the pBluescrip
xperiments and standard errors. The single (o) gene expression is compareas used to detect Nef (Fig. 6). Protein expression was
ore efficient when the nef-encoding plasmid was used
lone than when was it was combined with rev- and tat-
ncoding plasmids. HCMVnef was included as a positive
ontrol. Untransfected cells, empty vector pKCMV, and
Bluescript were included as negative controls.
-transfected with the respective rev-encoding plasmid, a tat-encoding
ositive control. Transfections with the p24- and tat-encoding plasmids
cells were transfected with either 2 mg of pBluescript DNA or 1 mg of
t was adjusted to 2 mg using the pBluescript noncoding plasmid. The
. The single (o) gene expression is compared with the combined (n)
with the respective nef-encoding plasmid. HCMVnef is included as a
ector pKCMV or 2 mg of pBluescript DNA as negative controls. In allcells co
as a p
, HeLa
amounsfected
mpty vt noncoding plasmid. The figure shows representative data of several
d with the combined (n) column.
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50 KJERRSTRO¨M ET AL.Immunogenicity of mice immunized with tat,- rev,-
or nef-expressing DNA
The biological effects of immunization were investi-
gated in separate experiments in mice with single-gene
administration and with the combination of pKCMVtat,
rev, and nef.
Tat immunity
Humoral responses to Tat. Tat immunization by single
genes elicited 100% responders to the rTat protein in
mice (Table 1) by in vitro B-cell stimulation. The response
to Tat representative peptides was measured, and 88% of
the tat immunized mice responded. In the groups immu-
ized with the combination of all three genes, all mice
esponded to both rTat and Tat peptides. There was thus
o difference in the frequency or magnitude of the re-
ponse between tat as a single gene and in the combi-
ation of rev and nef genes.
Epitope mapping of Tat peptide responses indicated
that B-cell epitopes are strong at aa 31–65 (Fig. 7A). Tat
immunization induced antibodies in vitro to the same
major epitopes when administered as a single gene and
in the combination formula.
DNA immunization did not result in significant IgG
seroconversion against HIV-1 Tat except for very low
titers in a few animals in each group. DNA immunization
thus resulted in priming of relevant B cell clones, but the
procedure was not sufficient to induce a complete anti-
body response. Subclass determination was performed
on sera reacting positively in IgG ELISA. IgG1/IgG2a
ratios of IgG responses to rTat and Tat peptides resulted
in ratios between 1.9 and 2.9, indicating stimulation of
both Th1 and Th2 responses (data not shown).
T-cell responses to Tat. The combination of all three
genes elicited a higher frequency of responders to rTat
and Tat peptides than did the pKCMVtat alone (Table 2).
Only 25% of the mice immunized with the single tat gene
T
B-Cell Stimulation in Vitro
Plasmid immunogen
No. of
mice
DNA
dose (mg) rTat
pKCMVtat 8 20–100 8/8 (100
KCMVrev 8 20–100 4/8 (50)
KCMVnef 7 20–100 ND
pKCMVtat, rev and nef combined 18 3 3 (20–100) 18/18 (100
Note: Groups with .90% reactivity are shown in bold. Percentages
a ND*, not done due to lack of cells.responded to rTat and 63% to Tat representative pep-
tides. Of the mice receiving the combination of genes,78% responded to rTat and 94% to Tat representative
t, Rev, and Nef Antigens
Frequency (%) of Responders
Tat
ptides rRev
Rev
peptides rNef
Nef
peptides CAG
/8 (88) 3/8 (38) ND ND ND 0/8 (0)
ND 8/8 (100) 5/8 (63) ND ND 0/8 (0)
ND 0/7 (0) ND 3/7 (43) 7/7 (100) NDa
18 (100) 17/18 (94) 14/18 (78) 16/18 (89) 18/18 (100) ND*
parentheses.FIG. 7. B-cell and T-cell epitopes following tat immunization. (A)
requency of B-cell epitope reactivity and mapping in vitro to recom-
inant Tat and Tat representative peptides in (C57BL/6)H2-b mice
mmunized with pKCMVtat, rev, and nef combined. The number of mice
n) reacting to the respective antigen is indicated. (B) Frequency of
-cell epitope reactivity and mapping in vitro to recombinant Tat and Tat
representative peptides in (C57BL/6)H-2b mice immunized withABLE 1
to Ta
pe
) 7
) 18/pKCMVtat, rev, and nef combined. The number of mice (n) reacting to
the respective antigen is indicated. Mean cpm for medium was 4946.
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51INTERACTIONS OF HIV DNA IMMUNOGENS IN VIVOmice immunized with single gene and mice immunized
with the combination of genes.
Epitope mapping analysis revealed strong T-cell
epitopes between aa 16 and 50 (Fig. 7B). The epitopes
were shared by mice immunized with single tat-encoding
plasmid and mice immunized with the combination of all
three plasmids. However, stronger reactions to the
epitopes were observed in mice that had received the
combination of plasmids.
Rev immunity
Humoral responses to Rev. Single rev gene adminis-
tration of 20–100 mg to mice elicited 100% responses in
in vitro B-cell stimulation to the rRev protein (Table 1) and
63% responders to Rev peptides.
The response to rRev elicited with the combination of
genes was as efficient as single rev gene administration.
However, the number of B-cell stimulation responders to
Rev peptides was slightly higher in the mice that had
received the combination of all three genes. The magni-
tude of the response to rRev elicited by single rev gene
immunization was, however, statistically stronger (P 5
0.002, Mann–Whitney U-test) than that induced by the
combination of genes (Fig. 8A).
Epitope mapping of Rev peptide responses indicated
that B-cell epitopes are strong at aa 18–50 (Fig. 8B). Rev
immunization induced antibodies in vitro to the same
major epitopes when administered as a single gene and
in the combination formula.
DNA immunization did not result in significant sero-
conversion against HIV-1 Rev except for very low titers in
a few animals in each group. DNA immunization thus
resulted in priming of relevant B-cell clones, but the
procedure was not sufficient to induce a complete anti-
body response. Subclass determination was performed
on sera reacting positively in IgG ELISA. IgG1/IgG2a
ratios of IgG responses to rRev and Rev peptides were
T
T-Cell Stimulation in
Plasmid immunogen
DNA
dose (mg)
No. of
mice rTat
PKCMVtat 20–100 8 2/8 (25
PKCMVrev 20–100 8 0/6
PKCMVnef 20–100 7 ND
pKCMVtat, rev and nef combined 3 3 (20–100) 18 14/18 (78
PKCMV 300 5 2/5 (40
Note: Groups with .90% reactivity are shown in bold. ND, not done
a Mice immunized with 50 mg followed by 10 mg pKCMVrev not rTabetween 2.2 and 3.9, indicating stimulation of both Th1
and Th2 responses (data not shown).
c
aT-cell responses to Rev. Twenty-five percent of the
mice immunized with the single rev gene showed spe-
cific T-cell proliferative responses to rRev and 75% to
Rev-representative peptides. The DNA administration in
the combination experiments elicited 28% responders to
rRev and 44% responders to Rev representative peptides.
The magnitude of the T-cell response to Rev peptides
was stronger in mice that had received the single rev
gene than in those that had received the combination of
genes (Fig. 8C, P 5 0.002, Mann–Whitney U-test).
The T-cell epitope pattern differed slightly between
ice immunized with the single rev gene and those
mmunized with the combination. Single-gene immu-
ized mice responded to epitopes present at aa 1–20
nd 31–100 (data not shown), while mice immunized with
he combination of all three genes responded to aa
8–50 (Fig. 8D).
ef immunity
Humoral responses to Nef. Nef immunization using
ingle nef gene administration to mice elicited 43% B-cell
timulation responders to rNef and 100% responders to
ef representative peptides (Table 1). Of the mice that
eceived the combination of genes, 89% responded to
Nef and 100% to Nef representative peptides. No differ-
nce in magnitude was seen between the single-nef-
ene immunized mice and the mice receiving the com-
ination of genes.
Epitope mapping of Nef peptide responses demon-
trated that major epitopes are found at the C-terminal
omain of the protein at aa 151–185 (Fig. 9A). Nef immu-
ization induced antibodies to the same major epitopes
hen administered as a single gene compared with the
ombination except that the N-terminal epitope reactivity
as more prominent in mice immunized with the single
ef gene.
DNA immunization did not result in significant sero-
Respective Antigen
Frequency (%) of Responders
Tat
ptides rRev
Rev
peptides rNef
Nef
peptides CAG
5/8 (63) 1/8 (13) ND ND ND 1/8 (13)
ND 2/8 (25) 6/8 (75) ND ND 0/8 (0)
ND 0/7 (0) ND 7/7 (100) 5/7 (71) 2/7 (29)
/18 (94) 5/18 (28) 8/18 (44) 13/18 (72) 11/18 (61) 0/18 (0)
1/5 (20) 0/5 (0) 1/5 (20) 0/5 (0) 0/5 (0) 0/5 (0)
ntages are in parentheses.
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mid.
54 KJERRSTRO¨M ET AL.resulted in priming of relevant B cell clones, but the
procedure was not sufficient to induce a complete anti-
body response. Subclass determination was performed
on sera reacting positively in IgG ELISA. IgG1/IgG2a
ratios of IgG responses to rNef and Nef peptides re-
sulted in ratios between 1.3 and 2.6, indicating stimula-
tion of both Th1 and Th2 responses (data not shown).
T-cell responses to Nef. All mice immunized with sin-
gle pKCMVnef (20–100 mg) responded to rNef (Table 2)
and 71% to Nef representative peptides in the T-cell
stimulation assay. Immunization with the combination of
plasmids elicited less responders to rNef (72%) and to
Nef representative peptides (61%). Single nef gene ad-
ministration thus resulted in a slightly higher number of
responders to rNef but also induced higher specific stim-
ulation to rNef than when nef was combined with the
other two genes (P 5 0.02, Mann–Whitney U-test; Fig.
9B).
Nef epitope mapping of T-cell stimulation responses
showed that the strongest cellular epitopes were present
at aa 151–205 (Fig. 9C).
All immune responses to Tat, Rev, and Nef were com-
pared to protein expression levels (Table 3) and a con-
cordance between interference at the level of protein
expression and interference of immunity was identified.
Unspecific responses
The empty vector pKCMV by itself elicited B- and T-cell
activation measured as responses to the Tat and Rev
antigens but not to the Nef antigens (Tables 1 and 2).
Forty percent of the mice responded to rTat protein and
20% to Tat peptides. No mice responded to rRev, but 20%
of mice showed Rev peptide-specific responses. None of
the mice responded to control antigen, however. The
plasmid preparation did not contain any lipopolysaccha-
rides. All these putatively unspecific responses have
been deducted from the above interpretations, but it is
T
Protein Expression Capacity Compared with Frequency of Resp
Antigen Immunogen
Protein
expression
capacity (%)a
Frequency of
B-cell
stimulation
responders (%)
Fr
Ig
res
Tat pKCMVtat 56 6 28 100
All genes combined 85 6 43 100
Rev pKCMVrev 93 6 19 100
All genes combined 109 6 60 100
Nef pKCMVnef 222 6 123 100
All genes combined 76 6 22 100
Note: Magnitude of antigen specific responses is not considered.
*Responses to both protein and peptides are summarized.
a Values related to standardized expression at several doses of plasconceivable that they represent an activation by these
plasmids of cross-reactive antibodies/T cells in the mice.DISCUSSION
To arrive at an optimal combination of genes, more
needs to be known about the interference between the
different genes in a multivalent vaccine both in vitro and
in vivo. In this study, we investigated the interference
between the HIV-1 regulatory genes with respect to in
vitro protein expression capacity and in vivo immunoge-
nicity.
Previously, we have performed two studies where we
characterized the immune responses to the regulatory
proteins of HIV-1 (Hinkula et al., 1997a,b). We evaluated
epitope pattern, the kinetics of immune responses, and
efficacy of different DNA dose responses using a com-
bination of the regulatory proteins and three structural
proteins of HIV-1 envelope (gp160) and gag (p241p17).
Further, different vector backbones and polyA signals
were used in these two studies. All vectors encoded the
human cytomegalovirus (CMV) immediate early promoter
and the ampicillin resistance gene, but different polyA
signals were used. No studies to evaluate possible an-
tagonism or synergy between components in the combi-
nation were performed. Structural HIV-1 genes were also
included in the mixture to mirror the HIV genome, pos-
sibly influencing responses to the regulatory genes. Dif-
ferent mouse strains were also used to evaluate efficacy
of induction of humoral and cellular responses.
Our present data show that Tat and Rev production
and biological activities were not affected by the co-
expression of the other two HIV-1 regulatory proteins
(Table 3). This seems consistent with the situation in vivo,
where Tat and Rev exert their functions in the presence
of each other and in the presence of Nef.
However, co-expression of Nef in vitro with the Tat and
Rev proteins, did result in a slight decrease of Nef ex-
pression in our titration studies (Table 3). One may hy-
pothesize that competition for transcription factors
to Tat, Rev and Nef Peptides or Recombinant Protein Antigens
y of
ody
s (%) Th1/2 ratio
B-cell epitope
pattern, aa
Frequency of
T-cell
stimulation
responders (%)
T-cell epitope
pattern, aa
.1 31–50 88 31–50
.1 31–65 100 16–50
.1 46–65 75 31–85
.1 18–50 50 18–50
.1 1–20, 151–185 100 151–185
.1 151–185 78 136–185ABLE 3
onders
equenc
G antib
ponder
88*
100*
63*
100*
100*
100*present in the transfected cells, or differences in the
preferred microenvironment around the promoter, will
55INTERACTIONS OF HIV DNA IMMUNOGENS IN VIVOlead to decreased Nef expression levels. Since all three
genes in this study used the same promoter and polyA
signal, enhancer elements unknown to us might be
present that benefit Tat and Rev expression. In HIV in-
fection, all three proteins are expressed from the same
set of multiply spliced mRNA early in infection. Nef ex-
pression is found in 80% of all transcripts, and one would
have assumed that there would be no interference with
Nef expression since it lacks HIV mRNA transcripts with
introns and since the Tat and Rev proteins are present.
In vivo studies were also performed regarding the
antigenicity of the genes as single or combined formu-
lations. Immune responses to the Tat protein were
slightly enhanced by the presence of the rev- and the
nef-encoding plasmids. One explanation would be the
increased concentration of murine CpG motifs present
when the plasmids were mixed. The amount of the spe-
cific genes was kept constant during these experiments
but not the total amount of DNA. Immunization with
unmethylated CpG motifs has been shown to stimulate
natural killer cells, macrophages, B cells, and dendritic
cells in vivo and in vitro (Behboudi et al., 2000; Hartmann
and Krieg, 2000; Klinman et al., 1999; Sato et al., 1996;
Weiner et al., 1997). All three plasmids and the empty
plasmid contain five murine immunostimulatory motifs
(GACGTC) and one human stimulatory motif
(AACGTCGA). Thus, the empty vector functions as the
control for the innate, unspecific stimulation activated by
the DNA plasmids in vivo.
Subclass determination indicated that both a Th1 type
and a Th2 type of response were stimulated as expected
using DNA vaccination. In our previous paper (Hinkula et
al., 1997b), we reported that at least one booster immu-
nization was required to obtain a detectable humoral IgG
responses to the Tat, Rev, and Nef proteins. However, in
this paper we saw that memory B cells were induced
already by a single injection of the relevant gene. T-
cellular responses could be detected already after the
primary DNA immunization with the regulatory genes.
We also found strong Tat B- and T-cell epitopes between
aa 31 and 65; this is consistent with previous findings
(Hinkula et al., 1997b). Since Tat is found both extracel-
lularly and intracellularly, both humoral and cellular re-
sponses specific for Tat are desirable.
The elicitation of immune responses to the Rev protein
was affected by co-expression of the Tat and Nef pro-
teins. Both B-cell stimulation reactivity and T-cell stimu-
lation indices were slightly stronger with the single rev
gene compared with the combination formula. The
epitope pattern to Rev indicated strong B- and T-cell
epitopes between aa 18 and 50, similar with single and
combined genes. Since Rev is found mainly intracellu-
larly, a strong cellular response toward Rev is desired.
When the nef gene was combined with the tat and rev
genes, Nef T-cell responses were reduced. An individual
decrease in Nef expression was observed in each set ofexperiments for protein expression capacity. T-cell re-
sponses were decreased by ;30% by rNef and by 40%
by Nef peptides. We believe that we see an effect of
combining the tat, rev, and nef genes of HIV-1 as sepa-
rate plasmids. To obtain the best immune response to
Nef, one should thus consider administering the nef and
rev genes alone or in combination with structural HIV
genes.
Epitope patterns to Nef were similar in mice immu-
nized with single and combined plasmids, showing aa
reactivity with the strongest epitopes at aa 151–185.
Since Nef molecules are found intracellularly and se-
creted from the cell, both cellular and humoral immuni-
ties are desired against Nef.
A study from Ayyavoo et al. (2000) describes the use of
a novel DNA vaccine cassette expressing three HIV-1
accessory genes under the control of a single promoter.
These authors investigated combined DNA vaccination
using a single plasmid encoding the three genes vif, vpu,
and nef of HIV. In their paper, no interference was ob-
served in the response obtained after the combined
plasmid immunization compared to when using the sin-
gle genes. Using a cassette encoding and expressing
the three regulatory genes of HIV-1 seems applicable to
avoid the interference we observed when using three
different plasmids. It would be more cost-effective to
develop cassettes compared to plasmids encoding sin-
gle genes.
The regulatory proteins of HIV have been shown to
influence a variety of host cell proteins that might inter-
fere with antigen presentation and capability of the host
to mount immune responses. Especially the Tat and Nef
proteins influence cells important for the immune sys-
tem. Nef downregulates both the CD4 receptor and MHC
class I molecules from the surface of infected cells
(Aiken et al., 1996; Cohen et al., 1999; Harris, 1996;
Schwartz et al., 1996). Expression of Nef might lead to
reduced viral epitope presentation by MHC class I mol-
ecules important for CTL recognition, and Nef would also
reduce interactions between CD4 and MHC class II
molecules between different effector–target cells. Nef
expression thus leads to reduced immune cell activation.
Tat induces Fas expression, suggesting a role of Tat in
Fas-mediated B-cell death (Huang et al., 1997). Both Tat
and Nef have been shown to influence the interleukin–2
(IL-2) receptor surface expression; IL-2 is the major cy-
tokine for proliferation and differentiation of T lympho-
cytes. Since no upregulation of the IL-2 receptor is found
in HIV infected patients, Tat and Nef are suspected to
disturb the IL-2 and IL-2 receptor communication (Green-
way et al., 1994; Puri et al., 1995). All these effects of the
early proteins make them attractive targets for immuni-
zation.
To our knowledge, this is the first report to show that
co-immunization with three genes that are co-expressed
in the natural virus infection can result in inhibition of
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56 KJERRSTRO¨M ET AL.both the protein expression efficacy and the develop-
ment of a specific immune response to one of the com-
ponents. This finding indicates that it is possible to
create potent multivalent vaccines but that the compo-
nents need to be compatible at the level of protein
expression in vitro and immunogenicity in vivo.
MATERIALS AND METHODS
lasmid constructs
The nef gene originates from the HIV-1strain HXB3
Accession No. M14100 and X03188), while the tat (Ac-
ession No. K03455 and M19921) and rev (Mermer et al.,
990) genes originate from the HXB2 strain of HIV-1. The
enes were amplified by PCR (Perkin–Elmer/Cetus) from
CMVtat, HCMVrev, and HCMVnef (Calarota et al., 1998,
999), using synthetic oligonucleotide primers (Life Tech-
ologies Inc., Rockville, MD), which corresponded to
9and 39 end-flanking sequences for the different genes
nd contained SalI/EcoRI restriction sites. The fragments
ere inserted into the pKCMV vector, creating the plas-
ids pKCMVtat, pKCMVrev, and pKCMVnef. The pKCMV
ector contains backbone sequences derived from
UC8, and the antibiotic selection marker is neomycin/
anamycin dependent (kanamycin kinase, EC No.
C2.7.1.95). The promoter used is the immediate early
romoter from human CMV and the polyA signal origi-
ates from HPV 16 (Fig. 1). Plasmids were grown in
scherichia coli (E. coli) DH5a (Life Technologies Inc.)
nd was purified by anion exchange resin (Qiagen
mbH, Hilden, Germany). Concentration and purity were
ssessed spectrophotometrically, and constructs were
onfirmed by restriction enzyme digestion followed by
BE agarose gel electrophoresis. Promoter, gene, and
olyA sequences were analyzed with an ABI prism Big
ye Terminator Cycle Sequencing Ready Reaction kit on
n ABI Prism 310 genetic analyzer (PE Biosystems, Fos-
er City, CA).
estern blot analysis
Protein expression from the plasmids encoding the
ingle genes was confirmed by Western blot (Fig. 2)
sing an ECL kit (Amersham Pharmacia Biotech Inc.,
iscataway, NJ). At 18–20 h before transfection, 200,000
eLa cells were plated with complete Eagle MEM 13 (2
M L-glutamine, 0.8 g/L sodium bicarbonate, 50 mg/L
penicillin/streptomycin) and 10% fetal calf serum (FCS)
(Life Technologies Inc.) in each well of a six-well plate.
The cells were incubated at 37°C in 5% CO2 for 24 h.
ransfection was performed with FuGENE 6 transfection
eagent (Roche Diagnostics Corp., Roche Molecular Bio-
hemicals, Indianapolis, IN) according to the manufac-
urer’s instructions. Two micrograms of the correspond-
ng DNA was used for the assay. The transfected cells
ere re-incubated for 24 h. The cells were washed twiceith ice-cold PBS before being harvested in Laemmli
ample buffer (Bio-Rad Laboratories, Hercules, CA) and
he proteins separated on a 12–15% SDS-ready gel (Bio-
ad Laboratories). The proteins were blotted to nitrocel-
ulose using a transfer buffer (25 mM Tris/192 mM gly-
ine in 20% methanol) at 100 V for 2–3 h. The blots were
hen blocked with 10% dried milk in PBS for 1 h at RT
efore being washed three times in 0.5% bovine serum
lbumin (BSA) with 0.5% Tween 20 in PBS. The strips
ere then hybridized to rabbit anti-Nef, anti-Tat, or anti-
ev polyclonal serum or mouse anti-Nef, anti-Tat, or
nti-Rev monoclonal antibodies (mab) (Ovod et al., 1992;
anki et al., 1994) overnight at RT. The nitrocellulose
strips were washed and incubated with horseradish per-
oxidase (HRP)-labeled goat anti-mouse immunoglobu-
lins or goat anti-rabbit immunoglobulins (DAKO A/S,
Glostrup, Denmark), both diluted 1/10,000, for 2 h at RT.
After a final wash, the membranes were soaked in ECL
solution (Amersham Pharmacia Biotech Inc.) and devel-
oped on film.
Immunofluorescence
Forty-eight hours before transfection, one chamber
slide with cover (Lab–Tek, Nalge Nunc International, Na-
perville, IL) was washed in 20% HCl at 1 4°C overnight.
The plates were washed with sterile water six times
before being seeded with 0.5 ml/well of 2 3 106 HeLa [in
Eagle’s MEM 13 with 2 mM L-glutamine, 0.8 g/L sodium
icarbonate, 50 mg/L penicillin/streptomycin, and 10%
fetal calf serum (FCS), Life Technologies Inc.]. The cells
were incubated at 37°C in 5% CO2 for 24 h. Transfection
as performed with FuGENE 6 (Roche Diagnostics
orp.) according to the manufacturer’s instructions. Two
icrograms of the corresponding DNA was used in this
ssay. The transfected cells were re-incubated for 24–48
. The cells were washed twice with ice-cold PBS before
eing fixed with 2% paraformaldehyde in PBS at 14°C
or 1 h. The cells were washed again and blocked with
BS containing 0.5% BSA and 0.05% Tween 20 at 14°C
or 1 h, then washed once more and incubated with
rimary antibodies in a 1/10 dilution in PBS. Primary
ntibodies used were rabbit anti-Tat, anti-Rev, and anti-
ef as well as mouse mabs against Tat, Rev, and Nef
Ovod et al., 1992; Ranki et al., 1994). The cells were
ncubated at 37°C for 1 h before being washed with PBS
nd blocked for 5 min at 14°C with PBS containing 0.5%
SA and 0.05% Tween 20. The cells were incubated with
ither FITC-conjugated F(ab9)2 fragment of rabbit anti-
mouse immunoglobulins or FITC-conjugated F(ab9)2 frag-
ment of swine anti-rabbit immunoglobulins (DAKO A/S) at
37°C for 30 min and then washed as before. The cells
were then incubated for 3 min with Evans Blue 0.003%,
pH 7.0 and the positive cells were evaluated by UV-light
microscopy (Fig. 3).
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57INTERACTIONS OF HIV DNA IMMUNOGENS IN VIVOQuantitative Tat expression
An enzyme-based ELISA was used to assay the
amount of CAT enzyme expressed from a CAT-encoding
plasmid. The plasmid, pNLCATw, carries the 59and 39LTR
from HIV-1 as promoter and polyA signal and thus needs
the Tat protein for expression of the encoded gene. HeLa
cells (200,000) were plated with complete Eagle’s MEM
13 (2 mM L-glutamine, 0.8 g/L sodium bicarbonate, 50
mg/L penicillin/streptomycin, and 10% FCS) (Life Tech-
nologies Inc.) and incubated at 37°C in 5% CO2 until
o-transfection 24 h later. Co-transfection was performed
ith FuGENE 6 transfection reagent (Roche Diagnostics
orp.) as recommended by the manufacturer. FuGENE 6
ransfection reagent (5 ml) was used for each sample.
he plasmid DNA encoding the tat genes was mixed
amounts used were 1, 0.1, 0.01, and 0.0001 mg) with the
NLCATw (1 mg) plasmid. The DNA amount was ad-
justed to a total of 2 mg for each transfection by addition
f the noncoding plasmid pBluescript. The pNLCATw (1
mg) was also used as a control for unspecific CAT ex-
pression. The transfected cells were incubated at 37°C
in 5% CO2 for 24 h before harvesting of the cells. The
ransfected cells were washed twice with ice-cold PBS
efore addition of 500 ml of harvesting buffer (0.5% Triton
X-100, 100 mM Tris–HCl, pH 7.4). The cells were scraped
and transferred to separate tubes in which they were
freeze-thawed by incubating them on dry ice for 5 min,
followed by 5 min at 37°C and vortexing for 10 s. This
was performed three times before the cell debris was
separated from the CAT-containing supernatant by cen-
trifugation at 4°C for 15 min at full speed. The samples
were diluted 1:100 and 1:1000 in 100 mM Tris–HCl, pH
7.5. The amount of CAT expressed was immediately
assayed by a CAT ELISA (Roche Diagnostics Corpora-
tion, Roche Molecular Biochemicals) as described by the
manufacturer. Briefly, a standard (1, 0.5, 0.25, 0.125, and 0
ng), consisting of recombinant CAT enzyme from E. coli,
was prepared with 100 mM Tris–HCl, pH 7.5. The stan-
dard is contained in the kit. Two hundred microliters of
the standard, cell supernatants, and diluted samples
was added in duplicates to the anti-CAT-antibody-coated
microtiter plate. The plate was incubated at 37°C for 1 h.
The plates were washed five times before 400 ng anti-
CAT-DIG antibodies were added to each well and the
plate was re-incubated for 1 h at 37°C. Again, the plate
as washed as above, and 30 mU anti-DIG-POD anti-
odies were added. The plate was incubated again as
bove and washed again before POD substrate was
dded. The plate was then incubated for 20 min at RT
efore the absorbence was measured at 405 nm (refer-
nce, 490 nm). A standard curve was drawn using linear
egression analysis. The concentration of the sample
as calculated according to: y 5 A 1 B*x, where y is the
absorbence value, A the value where the standard curvecrosses the y axis, B the slope of the curve, and x the
concentration of the sample.
Quantitative Rev expression
An antibody-mediated ELISA was used to assay the
amount of Gag (p24) protein expressed from a gag-
encoding plasmid. The gag-encoding plasmid, pNLgag-
Sty330, carries the 59 and 39 HIV LTR as promoter and
polyA signal, respectively, resulting in Rev and Tat de-
pendence for expression of the encoded gag. HeLa cells
(200,000) were plated with complete Eagle’s MEM 13 [2
M L-glutamine, 0.8 g/L sodium bicarbonate, 50 mg/L
penicillin/streptomycin, and 10% fetal calf serum (FCS)]
(Life Technologies Inc.) and incubated at 37°C in 5% CO2
until transfection 24 h later. Co-transfection was per-
formed with FuGENE 6 transfection reagent (Roche Di-
agnostics Corporation, Roche Molecular Biochemicals)
as recommended by the manufacturer. FuGENE 6 trans-
fection reagent (5 ml) was used for each sample. The
lasmid DNA encoding the rev genes was mixed
amounts used were 1, 0.1, 0.01, 0.001, and 0.0001 mg)
together with pNLgagSty330 (0.5 mg) and HCMVtat (0.5
mg) encoding the Tat protein. The pNLgagSty330 was
also used alone as a negative control (0.5 mg) for unspe-
cific gag production. The plasmid pBrev (the rev gene
nder the control of HIV-1 LTR) was included as a pos-
tive control. The DNA amount was adjusted to a total of
mg for each co-transfection by addition of the noncod-
ing plasmid pBluescript. The transfected cells were in-
cubated at 37°C in 5% CO2 for 24 h before harvesting of
the cells. The transfected cells were washed twice with
ice-cold PBS before addition of 500 ml of harvesting
uffer (0.5% Triton X-100, 100 mM Tris–HCl, pH 7.4). The
ells were scraped and transferred to separate tubes in
hich the cells were freeze-thawed by incubating them
n dry ice for 5 min, followed by 5 min at 37°C and
ortexing for 10 s. This was performed three times before
he cell debris were separated from the gag (p24) con-
aining supernatant by centrifugation at 4°C for 15 min at
ull speed. The amount of Gag expressed was immedi-
tely assayed by an HIV-1 p24 ELISA. Microtiter plates
Nunc-Immuno plate, MaxiSorp, Nalge Nunc Interna-
ional, Denmark) were coated with 20 mg/ml of polyclonal
rabbit IgG anti-HIV-1 core antigen (p24) in 0.1 M NaHCO3
buffer, pH 9.6, and incubated at RT overnight and stored
at 14°C until use. The plates were washed four times
with 0.15 M NaCl with 0.05% Tween 20 (washing buffer).
A standard curve was prepared through dilution (in PBS
including 0.02% merthiolate, 0.5% BSA and 0.05% Tween
20 and 0.5% Triton X-100) of an HIV-1 virion lysate. Con-
centrations used were from 2 down to 0.06 ng/ml; 0.1 ml
of all samples, the standard curve, cell supernatants, a
negative control, and a positive control, was added in
duplicates to the wells in the plate. The plate was cov-
ered with a sealing tape and incubated at RT over night.
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58 KJERRSTRO¨M ET AL.The plate was washed four times with washing buffer,
and 0.1 ml of three pooled HRP-conjugated mab anti
HIV-1 p24 antibodies was added to each well. The con-
jugate was diluted in PBS with 0.02% merthiolate, 0.5%
BSA, and 0.05% Tween 20 with 2% goat serum (optional).
The plate was incubated for 2 h at 37°C and washed as
bove. A substrate solution ((0.1 ml) of 1.2 mg/ml o-
phenylenediamine (OPD) in 0.05 M citrate buffer, pH 5.6,
with 0.01% H2O2, was added to each plate. After 30 min,
he reaction was terminated with 0.1 ml 2.5 M H2SO4, and
the absorbence was measured at 490 nm (reference
wavelength, 650 nm). A standard curve was drawn using
linear regression analysis and the concentration of the
sample was calculated according to: y 5 A 1 B*x, where
is the absorbence value, A the value where the stan-
ard curve crosses the y axis, B the slope of the curve,
nd x the concentration of the sample.
uantitative Nef ELISA
HeLa cells (200,000) were plated with complete Ea-
le’s MEM 13 [2 mM L-glutamine, 0.8 g/L sodium bicar-
bonate, 50 mg/L penicillin/streptomycin, and 10% fetal
alf serum (FCS), Life Technologies Inc.] and incubated
t 37°C in 5% CO2 for 24 h before transfection. Transfec-
ion was performed with FuGENE 6 transfection reagent
Roche Diagnostics Corp.) as recommended by the man-
facturer. FuGENE 6 transfection reagent (5 ml) was used
or each sample. The plasmid DNA encoding the nef
enes was mixed (amounts used were 2, 1.5, 1.0, 0.5, and
.25 mg) with pBluescript to adjust the total DNA amount
o a total of 2 mg for each transfection. Empty vector
(pKCMV) and untransfected cells were used as negative
controls, HCMVnef as a positive control. The transfected
cells were incubated at 37°C in 5% CO2 for 24 h and then
ashed twice with ice-cold PBS before the addition of
00 ml of 5XRIPA buffer (50 mM Tris buffer pH 7.4, 150
mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate). The cells were scraped and
transferred to separate tubes in which they were freeze-
thawed by incubating them on dry ice for 5 min, followed
by 5 min at 37°C and vortexing for 10 s. This was
performed three times before separating the cell debris
from the Nef-containing supernatant by centrifugation at
4°C for 15 min at full speed. A microtiter plate (Nunc-
Immuno plate, MaxiSorp, Nalge Nunc Internationa) was
coated with 1 mg/ml goat anti-mouse IgG1 (Southern
Biotechnology Associates Inc., Birmingham, AL) in 50
mM potassium phosphate buffer, pH 7.2 (PB buffer) over-
night at RT. The plate was washed three times in PB
buffer with 200 mM NaCl (PB-NaCl buffer) and saturated
for 1 h at RT with PB–NaCl buffer with 1% BSA. It was
then washed three times in PB–NaCl buffer with 0.1%
Triton X-100 before overnight incubation at 16°C with
PB–NaCl buffer with 1% sucrose and 1% BSA. The plate
was emptied and dried overnight at 16°C. Mouse anti-
t
nNef Mab (Ovod et al., 1992; Ranki et al., 1994) was diluted
1/100 in PB–NaCl buffer with 1% BSA and incubated at
16°C overnight. The plate was washed three times with
0.5 M KCl, followed by three times with deionized water.
It was then blocked at 16°C overnight with PB–NaCl
buffer with 1% sucrose and 1% BSA. The plate was
emptied and dried at RT for 1 h. The Nef-containing
samples, the cell supernatants, and a standard curve
consisting of recombinant Nef (kindly provided by B.
Kohlesein and V. Erfle, GSF, Germany) in PB–NaCl with
1% BSA ranging from 50 to 0.78 ng/ml were added to the
plate and incubated at 37°C for 2 h. The plate was
washed three times with 0.5% Triton X-100 in deionized
water. Polyclonal rabbit anti-Nef IgG was diluted 1/100 in
PB–NaCl buffer with 1% BSA and incubated on the plate
overnight at RT. The plate was washed three times with
0.5% Triton X-100 in deionized water, followed by the
addition of horse radish peroxidase (HRP)-conjugated
goat anti-rabbit IgG (DAKO A/S), diluted 1/2000 in PB–
NaCl buffer with 1% BSA, at 37°C for 1.5 h. The plate was
washed as before and 0.1 ml of a substrate solution of 1.2
mg/ml o-phenylenediamine (OPD) in 0.05 M citrate
buffer, pH 5.6, with 0.01% H2O2, was added. After 10 min,
he reaction was terminated with 0.1 ml 2.5 M H2SO4, and
the absorbence was measured at 490 nm (reference
wavelength, 650 nm). A standard curve was drawn using
linear regression analysis. The concentration of the sam-
ples was calculated according to: y 5 A 1 B*x, where y
is the absorbence value, A the value where the standard
curve crosses the y axis, B the slope of the curve, and x
the concentration of the sample.
Immunizations
Ten to 12-week-old (C57BL/6) H-2b mice transgenic for
human A2.01 were immunized twice at Weeks 0 and 4
with the corresponding DNA administered intramuscu-
larly by injection in the quadriceps muscle in both hind
legs. All plasmids were diluted in water. For single gene
administration (Tat n 5 8, Rev n 5 8, and Nef n 5 7), the
total DNA amount used was 10–50 mg at each immuni-
ation. These doses have been shown to be effective in
aising a Tat-, Rev-, and Nef-specific immune response
Hinkula et al., 1997b). For combined gene immunization,
he mice (n 5 18) were immunized twice at Weeks 0 and
with 3 3 (10–50) mg DNA at each immunization. The
DNA mixture was prepared from equal amounts of each
of the three plasmids to keep the gene content constant
in respect to the single-gene immunizations. Each
mouse in the combined gene immunization group re-
ceived 20–100 mg of each gene. The empty vector,
KCMV, was included as a control, using a 2 3 150 mg
ose. Mice were killed at Week 6. Blood was taken prioro the first immunization and 2 weeks after each immu-
ization.
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59INTERACTIONS OF HIV DNA IMMUNOGENS IN VIVOAntigens
The antigens used were recombinant Tat protein (Ce-
cilia Svanholm, MTC, Karolinska Institute, Sweden), re-
combinant Rev (in-house production) expressed in a bac-
ulovirus system, and affinity-purified recombinant Nef
antigen produced in E. coli (kindly provided by B Kohlsein
and V Erfle, GSF, Germany). The synthetic peptides used
were 20-mers with a 5-amino acid (5aa) overlap covering
the HIV-1 LAI strain regulatory proteins Tat, Rev, and Nef
(Accession No. K02013) (Myers et al., 1994). The peptides
were synthesized according to the 9-fluorenylmethoxy-
carbonyl method. Recombinant Tat and Nef (0.5mg/ml)
nd 1 mg/ml of Rev were used for coating ELISA plates
nd for T-cell stimulation. Synthetic peptides were used
t a concentration of 5 mg/ml, and concanavalin A (Con
A) was also used at a 5mg/ml concentration Aldrich Inc.,
aint Louis, MO).
-cell stimulation in vitro assay
Spleen cells (100,000/well) in 200 ml of RPMI 1640
upplemented with 5% inactivated fetal calf serum (FCS)
ere cultured for 72 h at 37°C in 96-well flat-bottomed
ell culture plates (Nunc) with stimulating peptide anti-
ens (10 mg/ml) or recombinant protein (1 mg/ml). The
lates were pre-coated with recombinant Tat, Rev, and
ef or Tat, Rev, and Nef peptides, diluted in 0.05 M
odium carbonate buffer (pH, 9.5–9.6), and incubated at
T overnight. After incubation, the plates were washed
nd goat anti-mouse IgG (H1L) HRP labeled (Bio-Rad
aboratories) were diluted 1/3000 in PBS with 0.5% BSA
nd added to the plates. The plates were incubated for
0 min at 37°C before being washed with 0.9% sodium
hloride with 0.05% Tween 20. Hydrogen peroxidase ac-
ivated orto-phenylenediamine (OPD; Aldrich) in 0.1 M
itric acid (pH 5.5) was added as a substrate. Color
evelopment was terminated with 100 ml of 2.5 M sulfuric
cid per well after 20-min incubation at RT. The absor-
ence was measured at 490 nm (reference wavelength,
50 nm). Specific, positive stimulation was assessed as
ptical density (OD) values higher than the cut-off value
mean value of the control group plus 2 SD).
easurement of antibody responses
For detection of specific antibody responses, ELISA
pecific for Tat, Rev, and Nef was used. Recombinant
roteins or representative peptides were diluted in 0.05
sodium carbonate buffer (pH, 9.5–9.6) and used for
oating 96-well plates (Nunc-Immuno plate, MaxiSorp,
alge Nunc International). Peptides were coated at a
oncentration of 10 mg/ml and recombinant proteins at 1
mg/ml for Tat and 0.5 mg/ml for Rev and Nef. Peptides
sed for peptide ELISA were as follows: Tat peptides
epresenting aa 31–50 and aa 46–65; Rev peptides rep-
esenting aa 1–20, aa 16–35, and 31–50; Nef peptidesepresenting 151–170, aa 166–185, and 181–205. The
lates were sealed and incubated overnight at RT before
eing washed four times with washing buffer (0.9% NaCl
ith 0.05% Tween 20) and blocked with 1% BSA in PBS
or 1 h at 37°C. Mouse sera were diluted 1/100, 1/300,
/900, and 1/2700 in PBS with 0.5% BSA and 0.05%
ween 20. Serum dilution (100 ml) was added per well,
nd the plates were incubated at 4°C overnight, followed
y washing as above. HRP-labeled goat anti-mouse im-
unoglobulin G (DAKO A/S) was diluted 1/2000. The
lates were incubated for 60 min at 37°C before being
ashed as above. Hydrogen peroxidase activated OPD
n 0.1 M citric acid (pH 5.5) was added as a substrate.
olor development was terminated with 100 ml of 2.5 M
ulfuric acid per well after 30-min incubation at RT. The
bsorbence was measured at 490 nm (reference wave-
ength, 650 nm). Samples were considered positive when
he optical density (OD) value was higher than the cut-off
alue (geometric mean value of the naive control group
lus 2 SD). Measurement of B-cell stimulation in vitro is
onsidered to be a more specific and sensitive measure-
ent of humoral responses than measurement of IgG
ecretion.
-cell proliferation assay
Spleen cells (200,000 per well) were cultured, in trip-
icates per sample, for 5–6 days in RPMI 1640 supple-
ented with 4 mM L-glutamine, 50 IU of penicillin per ml,
nd 50 mg of streptomycin per ml. Also included was 10%
fetal calf serum (Life Technologies Inc.) in the presence
of 0.1–1 mg of antigen, mitogen, control antigen, and
edium. A 50-ml volume of 3H-labeled thymidine was
added per well (1 mCi), the cells were incubated for 16 h,
and thymidine incorporation was measured in a
b-counter. The mean radioactivity (counts per minute,
cpm) was calculated for all triplicates of antigens, control
antigen, mitogen, and medium control. To obtain a value
for specific proliferation (stimulation index, SI), the mean
cpm value for each antigen was divided by the cpm value
for medium. Stimulation was considered positive if the SI
value was 3. All mice with a SI value for ConA ,5 were
excluded.
Subclass determination
For IgG subclass determination, a subclass specific
ELISA was performed according to the manufacturer
(Sigma, St. Louis, MO). Plates and sera were prepared
and incubated as above. After incubation of sera over-
night at 4°C, the plates were washed as above and
incubated for 2 h at 37°C with subclass specific antibod-
ies diluted 1:1000 in PBS with 0.5% BSA and 0.05% Tween
20. The plates were washed as above. HRP-labeled
rabbit anti-goat IgG (DAKO A/S) was diluted 1/1500 and
added to the plates, which were incubated for 60 min at
37°C before being washed as above. Hydrogen-peroxi-
BC
C
C
D
F
F
60 KJERRSTRO¨M ET AL.dase-activated OPD in 0.1 M citric acid (pH 5.5) was
added as a substrate. Color development was termi-
nated with 100 ml of 2.5 M sulfuric acid per well after
30-min incubation at RT. The absorbence was measured
at 490 nm (reference wavelength, 650 nm) and the IgG1
to IgG2a ratios were determined.
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